BACKGROUND: There is a consensus on the limited value of the QTc interval prolongation as a surrogate marker of drug cardiotoxicity and as a risk stratifier in inherited long QT syndrome (LQTS) patients. OBJECTIVE: We investigated the interest of repolarization morphology in the acquired and the inherited LQTS. METHODS: We analyzed 2 retrospective electrocardiographic (ECG) datasets from healthy on/off moxifloxacin and from genotyped KCNH2 patients. We measured QT, RR, and T-peak to T-end intervals, early repolarization duration (ERD) and late repolarization duration, T-roundness, T-amplitude, left (αL) and right slopes of T-waves. We designed multivariate logistic models to predict the presence of the KCNH2 mutation or moxifloxacin while adjusting for the level of QTc prolongation and the level of heart rate in LQT2 patients. Independent learning and validation sets were used. A list of 4,874 ECGs from 411 healthy individuals, 293 from 143 LQT2 carriers and 150 noncarrier family members were analyzed. RESULTS: In the moxifloxacin model, ERD was associated with the presence of the drug (odds ratio = 1.15 per ms increase, confidence interval 1.04 to 1.26, P = .0001) after adjustment for QTc. The model for the LQT2 revealed that left slope was associated with the presence of the KCNH2 mutation (odds ratio = 0.38 per 1.5 μV/ms decrease, confidence interval 0.23 to 0.64, P = .0002). Only T-roundness complemented QTc in the model investigating cardiac events in LQT2. CONCLUSIONS: These observations demonstrate that the phenotypic expression of KCNH2 mutations and the effect of IKr-inhibitory drug on the surface electrocardiogram are specific. Future research should investigate whether this phenomenon is linked to different level/form of loss functions of Ikr channels, and whether they could result in different arrhythmogenic mechanisms.
RCT Entities:
BACKGROUND: There is a consensus on the limited value of the QTc interval prolongation as a surrogate marker of drug cardiotoxicity and as a risk stratifier in inherited long QT syndrome (LQTS) patients. OBJECTIVE: We investigated the interest of repolarization morphology in the acquired and the inherited LQTS. METHODS: We analyzed 2 retrospective electrocardiographic (ECG) datasets from healthy on/off moxifloxacin and from genotyped KCNH2patients. We measured QT, RR, and T-peak to T-end intervals, early repolarization duration (ERD) and late repolarization duration, T-roundness, T-amplitude, left (αL) and right slopes of T-waves. We designed multivariate logistic models to predict the presence of the KCNH2 mutation or moxifloxacin while adjusting for the level of QTc prolongation and the level of heart rate in LQT2patients. Independent learning and validation sets were used. A list of 4,874 ECGs from 411 healthy individuals, 293 from 143 LQT2 carriers and 150 noncarrier family members were analyzed. RESULTS: In the moxifloxacin model, ERD was associated with the presence of the drug (odds ratio = 1.15 per ms increase, confidence interval 1.04 to 1.26, P = .0001) after adjustment for QTc. The model for the LQT2 revealed that left slope was associated with the presence of the KCNH2 mutation (odds ratio = 0.38 per 1.5 μV/ms decrease, confidence interval 0.23 to 0.64, P = .0002). Only T-roundness complemented QTc in the model investigating cardiac events in LQT2. CONCLUSIONS: These observations demonstrate that the phenotypic expression of KCNH2 mutations and the effect of IKr-inhibitory drug on the surface electrocardiogram are specific. Future research should investigate whether this phenomenon is linked to different level/form of loss functions of Ikr channels, and whether they could result in different arrhythmogenic mechanisms.
Authors: Markus Zabel; Marek Malik; Katerina Hnatkova; Vasilios Papademetriou; Andreas Pittaras; Ross D Fletcher; Michael R Franz Journal: Circulation Date: 2002-03-05 Impact factor: 29.690
Authors: Peter M Okin; Richard B Devereux; Richard R Fabsitz; Elisa T Lee; James M Galloway; Barbara V Howard Journal: Circulation Date: 2002-02-12 Impact factor: 29.690
Authors: Jean-Philippe Couderc; Stefan Kaab; Martin Hinterseer; Scott McNitt; Xiaojuan Xia; Anthony Fossa; Britt M Beckmann; Slava Polonsky; Wojciech Zareba Journal: J Clin Pharmacol Date: 2008-10-28 Impact factor: 3.126
Authors: Tanveer A Bhuiyan; Claus Graff; Jørgen K Kanters; Jimmi Nielsen; Jacob Melgaard; Jørgen Matz; Egon Toft; Johannes J Struijk Journal: Clin Drug Investig Date: 2015-11 Impact factor: 2.859
Authors: Alan Sugrue; Peter A Noseworthy; Vaclav Kremen; J Martijn Bos; Bo Qiang; Ram K Rohatgi; Yehu Sapir; Zachi I Attia; Peter Brady; Pedro J Caraballo; Samuel J Asirvatham; Paul A Friedman; Michael J Ackerman Journal: Ann Noninvasive Electrocardiol Date: 2017-04-21 Impact factor: 1.468
Authors: Arash Sadrieh; Stefan A Mann; Rajesh N Subbiah; Luke Domanski; John A Taylor; Jamie I Vandenberg; Adam P Hill Journal: J Physiol Date: 2013-04-03 Impact factor: 5.182
Authors: Andrew Sauer; Jane E Wilcox; Adin-Cristian Andrei; Rod Passman; Jeffrey J Goldberger; Sanjiv J Shah Journal: Circ Arrhythm Electrophysiol Date: 2012-03-30
Authors: Josef Halamek; Jean-Philippe Couderc; Pavel Jurak; Vlastimil Vondra; Wojciech Zareba; Ivo Viscor; Pavel Leinveber Journal: Ann Noninvasive Electrocardiol Date: 2012-08-13 Impact factor: 1.468
Authors: Alan Sugrue; Vaclav Kremen; Bo Qiang; Seth H Sheldon; Christopher V DeSimone; Yehu Sapir; Bryan L Striemer; Peter Brady; Samuel J Asirvatham; Michael J Ackerman; Paul Friedman; Peter A Noseworthy Journal: Cardiovasc Drugs Ther Date: 2015 Impact factor: 3.727
Authors: Bastiaan C Du Pre; Linda W Van Laake; Matthias Meine; Jeroen F Van der Heijden; Pieter A Doevendans; Marc A Vos; Toon A B Van Veen Journal: Front Physiol Date: 2017-08-15 Impact factor: 4.566